Cargando…

Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients

BACKGROUND: Bone metastases (BM) from colorectal cancer (CRC) are often accompanied by extraosseous metastases, resulting in a dismal prognosis. The present study aimed to determine the risk factors for BM in metastatic CRC (mCRC) and the prognostic factors for CRC patients with BM. METHODS: The stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Nan, Liu, Fangqi, Xi, Wenqi, Jiang, Jinling, Xu, Yun, Guan, Bingjie, Wu, Junwei, Zhou, Chenfei, Shi, Min, Zhu, Zhenggang, Xu, Ye, Liu, Jing, Zhang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184451/
https://www.ncbi.nlm.nih.gov/pubmed/34164509
http://dx.doi.org/10.21037/atm-21-2550
_version_ 1783704592137060352
author Wang, Nan
Liu, Fangqi
Xi, Wenqi
Jiang, Jinling
Xu, Yun
Guan, Bingjie
Wu, Junwei
Zhou, Chenfei
Shi, Min
Zhu, Zhenggang
Xu, Ye
Liu, Jing
Zhang, Jun
author_facet Wang, Nan
Liu, Fangqi
Xi, Wenqi
Jiang, Jinling
Xu, Yun
Guan, Bingjie
Wu, Junwei
Zhou, Chenfei
Shi, Min
Zhu, Zhenggang
Xu, Ye
Liu, Jing
Zhang, Jun
author_sort Wang, Nan
collection PubMed
description BACKGROUND: Bone metastases (BM) from colorectal cancer (CRC) are often accompanied by extraosseous metastases, resulting in a dismal prognosis. The present study aimed to determine the risk factors for BM in metastatic CRC (mCRC) and the prognostic factors for CRC patients with BM. METHODS: The study was based on a training cohort of 214 mCRC patients (of which, 101 patients had BM) from our center, and a validation cohort of 511 mCRC patients (of which, 173 patients had BM) from another institute. Risk and prognostic nomograms for BM were developed using univariate and multivariate analyses. The goodness of fit, discrimination, and calibration performance of the nomograms were assessed by R(2), concordance statistics (C-statistics), and the calibration curve. The results were internally validated using bootstrap resampling in the training cohort, and externally validated in the validation cohort. RESULTS: The novel BM risk nomogram comprised seven variables [degree of tumor differentiation, N-stage, serum alkaline phosphatase (ALP), lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA), liver metastasis, and lung metastasis]. It showed good performance, with an R(2) of 0.447 and a C-statistic of 0.846 [95% confidence interval (CI), 0.793 to 0.898] in the training cohort, and an R(2) of 0.325 and a C-statistic of 0.792 (95% CI, 0.750 to 0.834) in the validation cohort. The optimal cutoff value to identify individuals at low or high risk was 56% probability, with a sensitivity of 71.3% and a specificity of 89.4%. The prognostic nomogram included five factors (tumor differentiation, number of extra-BM organs, number of BM lesions, ALP, and LDH), and had an R(2) of 0.284 and a C-statistic of 0.723 (95% CI, 0.657 to 0.789) in the training set. This nomogram was externally validated in the validation cohort, with an R(2) of 0.182 and a C-statistic of 0.682 (95% CI, 0.638 to 0.726). CONCLUSIONS: The developed and validated risk and prognostic nomograms showed good performance for predicting the occurrence of BM in mCRC as well as the prognosis of CRC patients with BM. The risk nomogram can be used as a cost-effective preliminary screening tool prior to bone scanning.
format Online
Article
Text
id pubmed-8184451
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-81844512021-06-22 Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients Wang, Nan Liu, Fangqi Xi, Wenqi Jiang, Jinling Xu, Yun Guan, Bingjie Wu, Junwei Zhou, Chenfei Shi, Min Zhu, Zhenggang Xu, Ye Liu, Jing Zhang, Jun Ann Transl Med Original Article BACKGROUND: Bone metastases (BM) from colorectal cancer (CRC) are often accompanied by extraosseous metastases, resulting in a dismal prognosis. The present study aimed to determine the risk factors for BM in metastatic CRC (mCRC) and the prognostic factors for CRC patients with BM. METHODS: The study was based on a training cohort of 214 mCRC patients (of which, 101 patients had BM) from our center, and a validation cohort of 511 mCRC patients (of which, 173 patients had BM) from another institute. Risk and prognostic nomograms for BM were developed using univariate and multivariate analyses. The goodness of fit, discrimination, and calibration performance of the nomograms were assessed by R(2), concordance statistics (C-statistics), and the calibration curve. The results were internally validated using bootstrap resampling in the training cohort, and externally validated in the validation cohort. RESULTS: The novel BM risk nomogram comprised seven variables [degree of tumor differentiation, N-stage, serum alkaline phosphatase (ALP), lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA), liver metastasis, and lung metastasis]. It showed good performance, with an R(2) of 0.447 and a C-statistic of 0.846 [95% confidence interval (CI), 0.793 to 0.898] in the training cohort, and an R(2) of 0.325 and a C-statistic of 0.792 (95% CI, 0.750 to 0.834) in the validation cohort. The optimal cutoff value to identify individuals at low or high risk was 56% probability, with a sensitivity of 71.3% and a specificity of 89.4%. The prognostic nomogram included five factors (tumor differentiation, number of extra-BM organs, number of BM lesions, ALP, and LDH), and had an R(2) of 0.284 and a C-statistic of 0.723 (95% CI, 0.657 to 0.789) in the training set. This nomogram was externally validated in the validation cohort, with an R(2) of 0.182 and a C-statistic of 0.682 (95% CI, 0.638 to 0.726). CONCLUSIONS: The developed and validated risk and prognostic nomograms showed good performance for predicting the occurrence of BM in mCRC as well as the prognosis of CRC patients with BM. The risk nomogram can be used as a cost-effective preliminary screening tool prior to bone scanning. AME Publishing Company 2021-05 /pmc/articles/PMC8184451/ /pubmed/34164509 http://dx.doi.org/10.21037/atm-21-2550 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Wang, Nan
Liu, Fangqi
Xi, Wenqi
Jiang, Jinling
Xu, Yun
Guan, Bingjie
Wu, Junwei
Zhou, Chenfei
Shi, Min
Zhu, Zhenggang
Xu, Ye
Liu, Jing
Zhang, Jun
Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients
title Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients
title_full Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients
title_fullStr Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients
title_full_unstemmed Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients
title_short Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients
title_sort development and validation of risk and prognostic nomograms for bone metastases in chinese advanced colorectal cancer patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184451/
https://www.ncbi.nlm.nih.gov/pubmed/34164509
http://dx.doi.org/10.21037/atm-21-2550
work_keys_str_mv AT wangnan developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients
AT liufangqi developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients
AT xiwenqi developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients
AT jiangjinling developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients
AT xuyun developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients
AT guanbingjie developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients
AT wujunwei developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients
AT zhouchenfei developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients
AT shimin developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients
AT zhuzhenggang developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients
AT xuye developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients
AT liujing developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients
AT zhangjun developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients